MedPage Today on MSN
First Drug for Deadly Transplant Complication Gets FDA's Blessing
The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
Pain represents the cardinal symptom of osteoarthritis, yet its intensity, quality, and impact vary dramatically among ...
Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker ...
TipRanks on MSN
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt
InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...
As global regulators rethink tobacco control strategies, the U.S. FDA’s move toward a “chain of risk” framework has sparked fresh debate on harm reduction. To understand its implications for India, ...
Singapore has one of the highest life expectancies in the world, yet many individuals spend almost a decade in poor health ...
MedPage Today on MSN
FcRn Blockers Vie to Become First Approved Drug for Sjogren's Disease
FcRn blockers are approved for other indications: efgartigimod for adults with generalized myasthenia gravis and in ...
Zacks Investment Research on MSN
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA
Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...
Verywell Health on MSN
What Happens to Your Immunity When You Take Elderberry and Zinc Together
Elderberry and zinc both support immune health, but what happens when you combine them? Learn how these supplements work together to strengthen immunity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback